Latest News
Environmental Cost of AI and ML in Life Science: Is It Bad for the Planet?
During a lab internship, I spent three months counting cells under a microscope. One slide at a time, one cell at a time. Today a trained model can do that counting in seconds, and that speed raises a question about the environmental cost of AI. That is the promise of...
Latest News
What the Next Generation of GLP-1s Means for Pharmacists and Patients
GLP-1 receptor agonists (GLP-1 RAs) have reshaped the treatment of type 2 diabetes and obesity. But the next phase of GLP-1 therapy, and of incretin-based treatment more broadly, is likely to have implications that extend well beyond the approval of another...
Del-Desiran Next Steps: Will Novartis Continue After HARBOR?
Novartis has not yet said whether it will keep developing del-desiran, its drug for myotonic dystrophy type 1 (DM1). The del-desiran next steps depend on the full HARBOR dataset and on talks with regulators. On 27 October 2026, Novartis reported a USD 1.9 billion...
Interoperability Begins Where Data Exchange Ends
Standards and APIs can move information. True healthcare interoperability requires the governance, trust and workflow design that make the information usable. Healthcare has spent years treating interoperability as a problem of moving data. National exchange has...
Psychobiotics and Depression: Exploring the Gut–Brain Connection
Depression care continues to evolve as researchers explore why people respond differently to treatment. One area drawing attention is the relationship between the gut microbiome and the brain. Could psychobiotics, which target this connection, offer additional support...
Join The Future Of Life Sciences Media
In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.
Don’t wait for the media to pick up your story. Be the media.
Trending
More News
Rakuten Medical Appoints Former Takeda CEO Christophe Weber to Board
Rakuten Medical Appoints Christophe Weber as Vice Chairman and Ken Takeshita, M.D., as Director to Accelerate US Growth and Oncology Innovation Enhanced Board and leadership team, including the appointment of a new Chief Medical Officer, strengthens governance,...
Why Hormone Health Knowledge Could Improve Female Staff Retention
The life sciences sector is built on evidence, innovation and better health outcomes. So why is women’s hormone health at work still so often treated as a peripheral issue, asks Sarah Davies, Managing Director of Balance@Work? Life sciences organisations spend their...
Tozorakimab COPD Trial Data Reach Below the Eosinophil Gate
AstraZeneca released the full tozorakimab COPD trial results on 8 September 2026. The company presented them as a late breaker at the European Respiratory Society Congress in Barcelona. The slot was the ALERT-2 plenary session. The New England Journal of Medicine...
Section 232 Pharma Tariffs: What Changes on 29 September
On 29 September 2026, Section 232 pharma tariffs reach every company not named in Annex III. The default rate is 100 per cent ad valorem. It applies to patented finished medicines and their associated ingredients. That means active pharmaceutical ingredients and key...
Regenerative Biologics and Biomaterials in Modern Aesthetic Surgery
The Shift Toward Regenerative Surgery When I trained, the reconstructive mindset in plastic surgery was largely mechanical. The goal was to restore form by moving tissue, removing what was damaged, or replacing what was missing, while accepting some degree of scarring...
Coming Off Weight Loss Injections: The Oral Maintenance Option
Orforglipron (Foundayo) is now available in the UK following The Medicines and Healthcare products Regulatory Agency (MHRA) approval on 10 August, making the UK the first European country to license it for weight management and type 2 diabetes. The first oral...
Camizestrant Approval Makes ctDNA Progression a Regulatory Endpoint
The camizestrant approval granted by the US Food and Drug Administration on 4 September 2026 sets an oncology precedent. It is the first US clearance of a cancer therapy triggered by a resistance mutation found in blood. The agency made that claim itself. The trigger...
CBD Vaping: When Product Innovation Outpaces the Science
Early research offers insight, but major gaps remain in understanding long term respiratory effects The rapid rise of CBD vaping products has outpaced the science and regulatory frameworks needed to fully understand their health implications. While early research...
Neurodegeneration Pipeline 2026: Genetic Medicine Leads
Last updated 5 November 2026. The FDA accepted uniQure’s Huntington’s gene therapy application for priority review, with a target action date of 1 May 2027. The neurodegeneration pipeline looks very different from the one that opened 2026. Two events in the first week...
The Future of Collagen Hydrogels in Regenerative Medicine
Collagen hydrogels are still the benchmark for regenerative medicine because they provide cells with an environment that feels biologically familiar. However, the next challenge within this field is no longer proving whether or not collagen works, but in capably...
Novo Nordisk Halts Two IL-6 Heart Failure Trials for Futility
Novo Nordisk has stopped two Phase 3 IL-6 heart failure trials on the advice of an independent monitoring committee. The company notified trial investigators on Friday 4 September 2026. Trade press reported the decision on Monday 7 September. Both studies, HERMES and...
After EMBRAZE: The Wider Race to Preserve Muscle During GLP-1 Treatment
When results from the phase 2 EMBRAZE trial were published in Nature Medicine in June, apitegromab’s combination with tirzepatide became the most visible evidence yet that pharmacological muscle preservation during GLP-1 treatment might be achievable.¹ But...
Rakuten Medical Appoints Former Takeda CEO Christophe Weber to Board
Rakuten Medical Appoints Christophe Weber as Vice Chairman and Ken Takeshita, M.D., as Director to Accelerate US Growth and Oncology Innovation Enhanced Board and leadership team, including the appointment of a new Chief Medical Officer, strengthens governance,...
Why Hormone Health Knowledge Could Improve Female Staff Retention
The life sciences sector is built on evidence, innovation and better health outcomes. So why is women’s hormone health at work still so often treated as a peripheral issue, asks Sarah Davies, Managing Director of Balance@Work? Life sciences organisations spend their...
Tozorakimab COPD Trial Data Reach Below the Eosinophil Gate
AstraZeneca released the full tozorakimab COPD trial results on 8 September 2026. The company presented them as a late breaker at the European Respiratory Society Congress in Barcelona. The slot was the ALERT-2 plenary session. The New England Journal of Medicine...
Section 232 Pharma Tariffs: What Changes on 29 September
On 29 September 2026, Section 232 pharma tariffs reach every company not named in Annex III. The default rate is 100 per cent ad valorem. It applies to patented finished medicines and their associated ingredients. That means active pharmaceutical ingredients and key...
Regenerative Biologics and Biomaterials in Modern Aesthetic Surgery
The Shift Toward Regenerative Surgery When I trained, the reconstructive mindset in plastic surgery was largely mechanical. The goal was to restore form by moving tissue, removing what was damaged, or replacing what was missing, while accepting some degree of scarring...
Coming Off Weight Loss Injections: The Oral Maintenance Option
Orforglipron (Foundayo) is now available in the UK following The Medicines and Healthcare products Regulatory Agency (MHRA) approval on 10 August, making the UK the first European country to license it for weight management and type 2 diabetes. The first oral...
Camizestrant Approval Makes ctDNA Progression a Regulatory Endpoint
The camizestrant approval granted by the US Food and Drug Administration on 4 September 2026 sets an oncology precedent. It is the first US clearance of a cancer therapy triggered by a resistance mutation found in blood. The agency made that claim itself. The trigger...
CBD Vaping: When Product Innovation Outpaces the Science
Early research offers insight, but major gaps remain in understanding long term respiratory effects The rapid rise of CBD vaping products has outpaced the science and regulatory frameworks needed to fully understand their health implications. While early research...
Neurodegeneration Pipeline 2026: Genetic Medicine Leads
Last updated 5 November 2026. The FDA accepted uniQure’s Huntington’s gene therapy application for priority review, with a target action date of 1 May 2027. The neurodegeneration pipeline looks very different from the one that opened 2026. Two events in the first week...
The Future of Collagen Hydrogels in Regenerative Medicine
Collagen hydrogels are still the benchmark for regenerative medicine because they provide cells with an environment that feels biologically familiar. However, the next challenge within this field is no longer proving whether or not collagen works, but in capably...
Novo Nordisk Halts Two IL-6 Heart Failure Trials for Futility
Novo Nordisk has stopped two Phase 3 IL-6 heart failure trials on the advice of an independent monitoring committee. The company notified trial investigators on Friday 4 September 2026. Trade press reported the decision on Monday 7 September. Both studies, HERMES and...
After EMBRAZE: The Wider Race to Preserve Muscle During GLP-1 Treatment
When results from the phase 2 EMBRAZE trial were published in Nature Medicine in June, apitegromab’s combination with tirzepatide became the most visible evidence yet that pharmacological muscle preservation during GLP-1 treatment might be achievable.¹ But...
Featured Articles
Further News
Is RNA Potency the Problem? Creative Biolabs Webinar on saRNA Delivery
The next breakthrough in RNA therapeutics may depend less on making RNA more powerful and more on solving how efficiently it reaches and functions inside target cells. Creative Biolabs will host the upcoming webinar "Engineering saRNA Delivery Systems for...
Weekly News Roundup | 07 September 2026
Life science news 7 September 2026: two US approvals, a UK suspension, a Phase 3 failure and four global deals. PharmaEssentia won FDA approval for Besremi in essential thrombocythemia, a label expansion for the interferon therapy. The MHRA suspended Avacopan Vifor...
Alexander Disease Treatment Approved: What It Means for UK Access
The United States Food and Drug Administration has approved the first Alexander disease treatment. Zanvastro (zilganersen) was cleared on 3 September 2026 for paediatric and adult patients. Ionis Pharmaceuticals developed the antisense oligonucleotide. The decision...
Pelacarsen Trial Miss Leaves Lp(a) Lowering Unproven
Novartis has reported that the pelacarsen trial missed its primary endpoint. The Phase III study, called Lp(a)HORIZON, enrolled 8,323 patients with established cardiovascular disease and elevated lipoprotein(a). The company announced the topline result on 4 September...
Ivonescimab Overall Survival Win Leaves the Key Numbers Undisclosed
Akeso has reported that ivonescimab beat pembrolizumab on overall survival in a Chinese Phase III trial. HARMONi-2 is the fourth Phase III trial of ivonescimab to meet an overall survival endpoint. The ivonescimab overall survival result is the first against...
New Biology, New Opportunities in Women’s Health
Capital is moving into women’s health. But the science may give it even more reason to stay. Across the field, substantial unmet need is converging with rapidly advancing science and enormous areas of unexplored biology. Advances in genetics, molecular biology,...
Clinical Trials Roundup | 4 Sept 2026
Cytokinetics' aficamten meets both primary endpoints in the Phase 3 ACACIA-HCM trial in non-obstructive hypertrophic cardiomyopathy, Takeda and Protagonist's Mimrylo receives FDA approval as the first hepcidin mimetic for polycythaemia vera, Gilead's Bixlenvo is...
The Scale-Up Test
A lab result is only the beginning I have spent close to 20 years developing pharmaceutical, nutraceutical and consumer health products. One lesson has followed me through almost every role: a formula can work beautifully in the laboratory and still become a problem...
ACTO Achieves Veeva Gold Product Partner Status
Validated integrations with Veeva applications help life sciences field teams train, practice, and execute with approved content and real time intelligence Toronto and New York, 2 September 2026 ACTO, uniting human intelligence with empathetic AI in life sciences,...
Huntington Gene Therapy Submission Reaches FDA and MHRA
uniQure filed for regulatory approval of its Huntington’s disease gene therapy on 2 September 2026. The Huntington gene therapy submission went to two agencies. One is the US Food and Drug Administration. The other is the UK Medicines and Healthcare products...
GLP-1 Indications: The 2026 Regulatory Status Map
The list of approved GLP-1 indications now reaches well beyond weight loss and glycaemic control. Regulators in three major markets have licensed the class across cardiology, nephrology and hepatology. Other conditions carry positive phase 3 data but no licence at...
AI in MedTech: Accelerating the Product Development Lifecycle
Developing a new medical device is a lengthy, complex process that typically takes between three to seven years from conception to market [1]. For MedTech companies operating within highly regulated environments where compliance and patient safety are paramount,...
Further News
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.
Don’t wait for the media to pick up your story. Be the media.
See More Articles
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.













